Last 772.50 GBp
Change Today +5.00 / 0.65%
Volume 3.4M
REL On Other Exchanges
Symbol
Exchange
London
New York
Berlin
Frankfurt
OTC US
As of 11:35 AM 05/21/13 All times are local (Market data is delayed by at least 15 minutes).

reed elsevier plc (REL) Snapshot

Open
763.00 GBp
Previous Close
767.50 GBp
Day High
772.50 GBp
Day Low
761.50 GBp
52 Week High
04/3/13 - 800.50 GBp
52 Week Low
06/1/12 - 466.10 GBp
Market Cap
9.2B
Average Volume 10 Days
2.8M
EPS TTM
0.46 GBp
Shares Outstanding
1.2B
EX-Date
05/1/13
P/E TM
16.8x
Dividend
25.56 GBp
Dividend Yield
3.31%
Current Stock Chart for REED ELSEVIER PLC (REL)

Related News

No related news articles were found.

reed elsevier plc (REL) Related Businessweek News

View More BusinessWeek News

reed elsevier plc (REL) Details

Reed Elsevier PLC, through its subsidiaries, provides professional information solutions worldwide. The company’s Scientific, Technical & Medical segment offers information and workflow tools that enables researchers to generate insights in the advancement of scientific discovery; publishes science and technology research articles and book titles; and provides abstract and citation databases. This segment also offers medical journals, books, reference works, databases, and online information tools to medical researchers, doctors, nurses, allied health professionals, students, hospitals, research institutions, health insurers, managed healthcare organizations, and pharmaceutical companies. Its Risk Solutions segment provides data and analytics for the property and casualty, and life insurance carriers; risk management, identity verification, fraud detection, credit risk management, and compliance solutions for financial institutions; and investigative solutions to the United States federal, State, and local law enforcement and government agencies. The company’s Business Information segment offers data services, information, and marketing solutions to business professionals; produces industry critical data services, lead generation tools, and online community and job sites; and publishes business magazines. Its Legal segment provides legal, tax, regulatory news, and business information solutions to legal, corporate, government, accounting and academic markets. The company’s Exhibitions segment organizes exhibitions and conferences for the broadcasting, TV, music, and entertainment; building and construction; electronics and electrical engineering; alternative energy, oil, and gas; engineering, manufacturing, and processing; gifts; interior design; IT and telecoms; jewelry; life sciences and pharmaceuticals; marketing; property and real estate; sports and recreation; and travel sectors. Reed Elsevier PLC was founded in 1894 and is based in London, the United Kingdom.

Founded in 1894

reed elsevier plc (REL) Top Compensated Officers

Chief Executive Officer, Member of Executive ...
Total Annual Compensation: 2.2M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 444.1K GBP
Compensation as of Fiscal Year 2012.

reed elsevier plc (REL) Key Developments

Apex Affinity Selects Reed Elsevier plc's Gold Standard Drug Database

Reed Elsevier plc announced an agreement with Apex Affinity, provider of innovative prescription discount programs for uninsured and underinsured families nationwide. Apex has selected Elsevier's Gold Standard Drug Database for providing current and accurate drug content to enhance its member products, including a new consumer drug reference portal. Apex leverages the purchasing power of millions of consumers to negotiate deep discounts on brand-name and generic prescriptions at nearly all major big box stores, drug store chains and independent neighborhood pharmacies. Apex will use Elsevier's Gold Standard Drug Database to enable members to compare drug pricing, look-up accurate dosage information, and learn about alternative therapies and what a medication is used for and what it does. The Gold Standard Drug Database content is updated daily and has a peer-reviewed editorial process in place to ensure the highe accuracy of drug product information, drug pricing and patient education information. Apex will benefit from the database's modern technical architecture and flexible implementation, which distinguishes Gold Standard Drug Database from other drug databases.

Reed Elsevier plc Announces Collaboration with Geological Society Of America to Add over 60,000 Maps to Geofacets Research Tool

Reed Elsevier plc announced its collaboration with The Geological Society of America (GSA). The collaboration will formally launch in September through the integration of more than 60,000 geological maps from GSA's journals, book series and the comprehensive Decade of North American Geology compendium into Geofacets, Elsevier's premier research tool for geoscientists working in exploration for the oil and gas and metals and mining industries. The move will bring the total number of maps in Geofacets to over 300,000, providing a comprehensive resource for Geofacets users to investigate potential areas for exploration in more detail than ever. The GSA will be the large 3(rd) party content contributor to Geofacets' maps database to date, providing maps from its range of publications stretching back to 1934. As a result, exploration teams using Geofacets will have more confidence in their technical evaluations of geographic areas for potential energy and mineral sources. For the GSA and its 25,000 members across 103 countries, the collaboration will allow the society to expand the reach of its maps: from its established position with academic users to those in the applied sector that need its information to make the best decisions possible. The 60,000 maps are collated from GSA's journals, including the Geological Society of America Bulletin and Geology, GSA's monthly journal that has been recognized as the most-cited geology publication for the past six years. Maps are also taken from GSA's four book series and the comprehensive Decade of North American Geology compendium.

Reed Elsevier plc Launches Genomics Data App in Collaboration with Illumina

Reed Elsevier plc announced the launch of the Genomics Data app in collaboration with Illumina, a sequencing and array-based solutions provider for genetics research. The app allows researchers to share large data sets in Illumina's BaseSpace cloud, where they can easily be reviewed and included in Elsevier's open access journal, Genomics Data. The BaseSpace app serves as a gateway, opening data stored in the cloud to the publishing environment for expert peer review and wide dissemination in the form of a professional publication. Through BaseSpace, authors and reviewers will also have additional access to analytical tools, further enhancing Genomics Data's peer review process. This enhanced review option can give an article attached to the data set added credibility because reviewers are in the position to reproduce the analysis that the authors did.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REL:LN 772.50 GBp +5.00

REL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for REL.
View Industry Companies
 

Industry Analysis

REL

Industry Average

Valuation REL Industry Range
Price/Earnings 15.5x
Price/Sales -- Not Meaningful
Price/Book 6.9x
Price/Cash Flow 15.2x
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REED ELSEVIER PLC, please visit www.reed-elsevier.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.